Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (3688)	6/23/1998 7:38:00 PM
From: James Baker	Respond to of 9523

*<<<<<- See how MUSE is a one-product company at the moment, I'll ask if MUSE the product has a cult-like following?>>>>> It would appear that over 2000 refills per week means that there is a group of successful MUSE patients that are using this product regularly. If reading the press and Internet mean anything, it is VIAGRA that has the "CULT-like following"!!!!! Jim Viagra with caps not spell checked...hummm

To: blankmind who wrote (3688)	6/23/1998 10:24:00 PM
From: BigKNY3	Read Replies (3) \| Respond to of 9523

Blank: MUSE currently has a core base of 2,000-3,000 new Rxs per week down from an average of 12,500 in 1997. The "coattail" effect of new specification from Viagra failures is no where to be seen. Wole Fayemi is definitely having sleepless nights based on his continuing expert analysis of VVUS for C. Roth. My best guess is that the vast majority of the 20-35% of ED patients who are not successful with Viagra still do not view MUSE as a viable option. Given the increased marketing expenses and the changing HMO ED drug reimbursement policies, if MUSE can not regain new Rx levels of over 7,500 per week, it is probable that VVUS will not make it to the year 2000. BigKNY3